HCM

HUTCHMED (China) Ltd

Add to Watchlist

Advanced Chart

18.310

-0.9(-4.685%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

18.790

Open

18.790

VWAP

18.24

Vol

45.07K

Mkt Cap

15.97B

Low

18.200

Amount

822.21K

EV/EBITDA(TTM)

Total Shares

170.73M

2.53B

EV/OCF(TTM)

5.08K

P/S(TTM)

5.18

HUTCHMED (China) Ltd is an investment holding company principally engaged in the manufacture and sale of pharmaceuticals. The Company operates its business through two segments. Oncology Immunology segment is engaged in the discovery, development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. Among it, research and development (R&D) includes research and development activities covering drug discovery, development, manufacturing and regulatory functions, out-licensing of in-house developed drugs, as well as administrative activities to support research and development operations, marketed products comprises the invoiced sales, marketing, manufacture and distribution of drugs developed from research and development activities. Other Ventures segment is engaged in the other commercial businesses which include the sales, marketing, manufacture and distribution of other prescription drugs and healthcare products.

2 Analyst Rating

13.87% Upside

Wall Street analysts forecast HCM stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for HCM is 20.85 USD with a low forecast of 14.70 USD and a high forecast of 27.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

1 Buy

1 Hold

0 Sell

Moderate Buy

13.87% Upside

Current: 18.310

Low

14.70

Averages

20.85

High

27.00

13.87% Upside

Current: 18.310

Low

14.70

Averages

20.85

High

27.00

BofA

Buy

upgrade

$27 -> $28

2025-07-22

Reason

BofA

Price Target

$27 -> $28

2025-07-22

upgrade

Buy

Reason

BofA raised the firm's price target on Hutchmed to $28 from $27 and keeps a Buy rating on the shares. The firm updated its model to include a revenue build for tazemetostat and adjust expectations slightly for operating expenses, the analyst tells investors in an earnings preview for its small-to-mid cap biotech coverage.

HSBC

Buy

Hold

downgrade

$14.70

2025-05-13

Reason

HSBC

Price Target

$14.70

2025-05-13

downgrade

Buy

Hold

Reason

HSBC downgraded Hutchmed to Hold from Buy with a $14.70 price target.

Goldman Sachs

Paul Choi

Hold

Maintains

$17 → $19

2024-08-01

Reason

Goldman Sachs

Paul Choi

Price Target

$17 → $19

2024-08-01

Maintains

Hold

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for HUTCHMED (China) Ltd (HCM.O) is 8.13, compared to its 5-year average forward P/E of 19.94. For a more detailed relative valuation and DCF analysis to assess HUTCHMED (China) Ltd 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

19.94

Current PE

8.13

Overvalued PE

359.63

Undervalued PE

-319.75

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-31.68

Current EV/EBITDA

-176.97

Overvalued EV/EBITDA

4.17

Undervalued EV/EBITDA

-67.54

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Fair

5Y Average PS

5.68

Current PS

4.71

Overvalued PS

9.77

Undervalued PS

1.60